Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any retinitis pigmentosa in which the cause of the disease is a mutation in the PDE6G gene.
Features include always present findings: Constriction of peripheral visual field and Reduced visual acuity. 8 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Eyes | 3 | Cystoid macular edema, Optic disc pallor, Attenuation of retinal blood vessels |
PDE6G function has not been fully characterized.
Retinitis pigmentosa 57 is associated with mutations in the PDE6G gene on chromosome 17.
Genetic testing for PDE6G is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for retinitis pigmentosa 57 has been reported in the published literature.
Phenotype severity distribution: 2 always present features.
No clinical trials have been registered for retinitis pigmentosa 57.
53 publications have been identified in PubMed for retinitis pigmentosa 57. Research spans Epidemiology / Natural History (45%), Basic Science / Preclinical (23%), and Diagnostic / Biomarker (9%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 24 | 45% |
Data assembled from 5 of 12 sources · Last updated Sep 18, 2026, 1:26 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
1 |
Bone spicule pigmentation of the retina |
Age of onset: adulthood.
Laboratory research
12 |
23% |
Testing and diagnosis research | 5 | 9% |
Patient case studies | 5 | 9% |
Research summaries | 4 | 8% |
Clinical study results | 2 | 4% |
New treatment approaches | 1 | 2% |
Parekh BJ (2026). [PMID: 41760091](https://pubmed.ncbi.nlm.nih.gov/41760091/). *Clin Exp Ophthalmol*. [Basic Science / Preclinical]
Karuntu JS (2026). [PMID: 40530429](https://pubmed.ncbi.nlm.nih.gov/40530429/). *Acta Ophthalmol*. [Epidemiology / Natural History]
Al-Moujahed A (2026). [PMID: 41891913](https://pubmed.ncbi.nlm.nih.gov/41891913/). *Ophthalmic Surg Lasers Imaging Retina*. [Epidemiology / Natural History]
Marsh K (2026). [PMID: 41697461](https://pubmed.ncbi.nlm.nih.gov/41697461/). *Pharmacoecon Open*. [Epidemiology / Natural History]
Marsal-Olivan A (2026). [PMID: 42071123](https://pubmed.ncbi.nlm.nih.gov/42071123/). *J Assist Reprod Genet*. [Diagnostic / Biomarker]
Eriksen KO (2026). [PMID: 40977613](https://pubmed.ncbi.nlm.nih.gov/40977613/). *Acta Ophthalmol*. [Basic Science / Preclinical]
Most JA (2026). [PMID: 40743462](https://pubmed.ncbi.nlm.nih.gov/40743462/). *Retina*. [Diagnostic / Biomarker]
Hong Y (2026). [PMID: 41242591](https://pubmed.ncbi.nlm.nih.gov/41242591/). *Am J Ophthalmol*. [Epidemiology / Natural History]
Long Y (2026). [PMID: 41480687](https://pubmed.ncbi.nlm.nih.gov/41480687/). *Int J Mol Med*. [Review / Meta-Analysis]
Schofield D (2026). [PMID: 42168561](https://pubmed.ncbi.nlm.nih.gov/42168561/). *Eye (Lond)*. [Review / Meta-Analysis]